Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL4 trial of weekly somapacitan versus daily Norditropin in prepubertal children with growth hormone deficiency
MOH_2019-03-19_004919Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in growth hormone deficiency (GHD) comparing Weekly somapacitan with Daily Norditropin (2 arms). Started Jan 2019; status: completed.
02
Drugs
somapacitansomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on MOH_2019-03-19_004919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-19_004919.